We are live on ! Find out more
BC

Boxer Capital Portfolio holdings

AUM $2.04B
1-Year Est. Return 108.39%
This Fund
S&P 500
This Quarter Est. Return
+30.58%
1 Year Est. Return
+108.39%
3 Year Est. Return
+261.8%
5 Year Est. Return
+1,135.09%
10 Year Est. Return
–
AUM
$2.89B
AUM Growth
+$619M
Cap. Flow
+$427M
Cap. Flow %
14.76%
Top 10 Hldgs %
55.7%
Holding
79
New
14
Increased
13
Reduced
2
Closed
4

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$117M
2
PMVP icon
PMV Pharmaceuticals
PMVP
+$83.5M
3
ODT
Odonate Therapeutics, Inc. Common Stock
ODT
+$52.2M
4
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$48.2M
5
RLAY icon
Relay Therapeutics
RLAY
+$47.7M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$107M
2
PRNB
Principia Biopharma Inc. Common Stock
PRNB
+$36.3M
3
TRIL
Trillium Therapeutics Inc.
TRIL
+$33M
4
LABD icon
Direxion Daily S&P Biotech Bear 3X ETF
LABD
+$6.45M
5
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.49M

Sector Composition

Rank Sector Weight
1 Healthcare 85.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IMMU
1
DELISTED
Immunomedics Inc
IMMU
$383M 13.22%
4,500,000
-2,106,000
-32% -$107M
ONC
2
BeOne Medicines Ltd
ONC
$32.8B
$319M 11.03%
1,114,188
+189,188
+20% +$44.5M
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$293M 10.13%
1,765,560
– –
RVMD icon
4
Revolution Medicines
RVMD
$39.9B
$115M 3.98%
3,309,264
+350,000
+12% +$9.69M
ITOS
5
DELISTED
iTeos Therapeutics
ITOS
$107M 3.7%
+4,345,016
New +$117M
SWTX
6
DELISTED
SpringWorks Therapeutics
SWTX
$99M 3.42%
2,075,905
– –
PMVP icon
7
PMV Pharmaceuticals
PMVP
$59.2M
$80.5M 2.78%
+2,268,236
New +$83.5M
SGEN
8
DELISTED
Seagen Inc. Common Stock
SGEN
$78.3M 2.71%
400,000
– –
ODT
9
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$69.9M 2.42%
5,207,086
+1,843,709
+55% +$52.2M
SAGE
10
DELISTED
Sage Therapeutics
SAGE
$66.9M 2.31%
1,094,000
– –
BDTX icon
11
Black Diamond Therapeutics
BDTX
$96.8M
$60.9M 2.1%
2,014,858
– –
ALLK
12
DELISTED
Allakos
ALLK
$55M 1.9%
675,000
– –
RLAY icon
13
Relay Therapeutics
RLAY
$4.1B
$53.3M 1.84%
+1,251,959
New +$47.7M
ICPT
14
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$48.8M 1.68%
1,176,000
+1,050,000
+833% +$48.2M
NRIX icon
15
Nurix Therapeutics
NRIX
$2.41B
$47.3M 1.63%
+1,354,392
New +$34.1M
ARGX icon
16
argenx
ARGX
$53.4B
$44.9M 1.55%
170,926
– –
CGEN icon
17
Compugen
CGEN
$222M
$38.7M 1.34%
2,383,673
– –
ESPR
18
DELISTED
Esperion Therapeutics
ESPR
$36.2M 1.25%
975,000
– –
RCUS icon
19
Arcus Biosciences
RCUS
$3.55B
$35.7M 1.23%
2,084,883
– –
SNDX icon
20
Syndax Pharmaceuticals
SNDX
$1.69B
$33.8M 1.17%
2,287,782
– –
RCKT icon
21
Rocket Pharmaceuticals
RCKT
$340M
$33.5M 1.16%
1,466,051
– –
FOLD
22
DELISTED
Amicus Therapeutics
FOLD
$32.8M 1.13%
2,325,000
– –
KURA icon
23
Kura Oncology
KURA
$800M
$32.2M 1.11%
1,050,289
+205,500
+24% +$4.54M
GOSS icon
24
Gossamer Bio
GOSS
$82.9M
$31.8M 1.1%
2,562,358
– –
RNAM
25
DELISTED
Avidity Biosciences
RNAM
$31.6M 1.09%
1,121,327
– –
1
2 3 4

Similar funds

FTDI
First Trust Direct Indexing Boston, Massachusetts $1.87B AUM 43.63% 1-Year Est. Return
CIM
Contrarius Investment Management St. Helier, Jersey $1.76B AUM 35.87% 1-Year Est. Return
PRO
Pensioenfonds Rail & OV Utrecht, Netherlands $1.44B AUM 23.73% 1-Year Est. Return
GFS
GYL Financial Synergies West Hartford, Connecticut $1.33B AUM 34.46% 1-Year Est. Return
ECM
Ensemble Capital Management San Francisco, California $1.18B AUM 41.81% 1-Year Est. Return
CIP
Chartwell Investment Partners Berywn, Pennsylvania $2.91B AUM 40.48% 1-Year Est. Return
SEC
Seven Eight Capital New York $1.11B AUM 29.48% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Boxer Capital's Q3 2020 Portfolio in Review

As of Q3 2020, Boxer Capital held 79 positions worth $2.89B, up 27% from $2.27B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Boxer Capital deployed $427M of net new capital in Q3 2020, opening 14 new positions and adding to 13 existing holdings. Its largest new stake was iTeos Therapeutics: 4,345,016 shares worth $107M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 86% a quarter earlier.

On the sell side, the largest reduction was Immunomedics Inc, an estimated $107M trimmed.

  • Boxer Capital's largest Q3 2020 buy was iTeos Therapeutics: 4,345,016 shares worth $107M.
  • Boxer Capital added most to Odonate Therapeutics, Inc. Common Stock in Q3 2020, an estimated $52.2M increase.
  • Boxer Capital's biggest Q3 2020 reduction was Immunomedics Inc, cutting an estimated $107M.
  • Boxer Capital fully exited Principia Biopharma Inc. Common Stock in Q3 2020, selling an estimated $36.3M.
  • Boxer Capital's ten largest holdings make up 56% of its $2.89B portfolio in Q3 2020.
  • Boxer Capital opened 14 new positions and closed 4 in Q3 2020.
  • Boxer Capital's portfolio value rose 27% quarter-over-quarter to $2.89B.

Based on Boxer Capital's 13F filing for Q3 2020, filed 16 Nov 2020.